Francesco Dati
Research Subjects
Francesco Dati has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
Armin Steinmetz
1 shared publicationGérard Denoyel
Laboratoire Marcel Merieux, 19 Avenue Tony Garnier, BP 7322, F-69357 Lyon, France
1 shared publicationJillian R. Tate
1 shared publicationJosef van Helden
Labor Dr. Stein & Kollegen, Wallstrasse 10, D-41061 Moenchengladbach, Germany
1 shared publicationSantica M. Marcovina
1 shared publication
Latest Publications
- 7 January 2004
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 42 (6) , 670-6
First WHO/IFCC International Reference Reagent for Lipoprotein(a) for Immunoassay – Lp(a) SRM 2B
Lipoprotein(a) is an important predictor of cardiovascular disease risk. The lack of internationally accepted standardization has impeded the broad application of this lipoprotein in laboratory medicine. The International Federation of Clinical Chemistry and Laboratory Medicine (IFCC), through its Working Group on Lipoprotein(a) and together with research institutions and several diagnostic companies, have succeeded in developing an international reference material that is intended for the transfer of a lipoprotein(a) concentration to manufacturers' master calibrators. IFCC SRM 2B has recently been accepted by the WHO Expert Committee on Biological Standardization as the ‘First WHO/IFCC International Reference Reagent for Lipoprotein(a) for Immunoassay’. The assigned unitage of 0.1071 nanomoles of lipoprotein(a) per vial is traceable to the consensus reference method for lipoprotein( a) and will enable conformity by diagnostic companies to the European Union's Directive on In vitro Diagnostic Medical Devices for the metrological traceability of calibrator materials.
- 7 January 2004
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 42 (6) , 670-6
First WHO/IFCC International Reference Reagent for Lipoprotein(a) for Immunoassay – Lp(a) SRM 2B
Lipoprotein(a) is an important predictor of cardiovascular disease risk. The lack of internationally accepted standardization has impeded the broad application of this lipoprotein in laboratory medicine. The International Federation of Clinical Chemistry and Laboratory Medicine (IFCC), through its Working Group on Lipoprotein(a) and together with research institutions and several diagnostic companies, have succeeded in developing an international reference material that is intended for the transfer of a lipoprotein(a) concentration to manufacturers' master calibrators. IFCC SRM 2B has recently been accepted by the WHO Expert Committee on Biological Standardization as the ‘First WHO/IFCC International Reference Reagent for Lipoprotein(a) for Immunoassay’. The assigned unitage of 0.1071 nanomoles of lipoprotein(a) per vial is traceable to the consensus reference method for lipoprotein( a) and will enable conformity by diagnostic companies to the European Union's Directive on In vitro Diagnostic Medical Devices for the metrological traceability of calibrator materials.
- 1 January 2004
- Vol. 50, 53-61
An update on laboratory productivity with infectious disease assays on the Bayer ADVIA Centaur Immunoassay System.
New biological materials and advances in robotic and computer technologies have enabled the development of automated systems designed for high-performance infectious disease immunoassays and nucleic acid amplification. The fully automated, random access Bayer ADVIA Centaur immunoassay system, offering testing for fertility, therapeutic drug monitoring, infectious disease, allergy, cardiovascular, anemia, oncology, TDMs and thyroid, has been specifically designed for use in large-volume laboratories. New immunoassay tests have been developed for the ADVIA Centaur for the hepatitis A virus, hepatitis B virus, hepatitis C virus and HIV. These assays have undergone extensive performance evaluation using samples designated in the CTS in support of obtaining the Communautés Européennes (CE) mark for European market distribution. The ADVIA Centaur Immunoassay System represents an optimal platform for infectious disease testing because of its flexibility in allowing many different assay formats and protocols with multiple incubation steps and washes coupled with its combination of magnetic particle separation and chemiluminescent detection. Additional quality features of the system design are the sample integrity verification/check, the use of disposable sample pipette tips, clot detection, the ability for sensing liquid levels, the reagent aspiration verification/check, the automatic cascade reflex testing, repeat testing, and automated reagent inventory. The ADVIA Centaur has a maximum test throughput of 240 tests per hour. Minimal hands-on time is required as a result of the large onboard capacity for reagents and supplies combined with automated maintenance and monitoring features, which streamline operations and result in a walk-away through-put of up to 840 tests.
- 1 January 2004
- Vol. 50, 53-61
An update on laboratory productivity with infectious disease assays on the Bayer ADVIA Centaur Immunoassay System.
New biological materials and advances in robotic and computer technologies have enabled the development of automated systems designed for high-performance infectious disease immunoassays and nucleic acid amplification. The fully automated, random access Bayer ADVIA Centaur immunoassay system, offering testing for fertility, therapeutic drug monitoring, infectious disease, allergy, cardiovascular, anemia, oncology, TDMs and thyroid, has been specifically designed for use in large-volume laboratories. New immunoassay tests have been developed for the ADVIA Centaur for the hepatitis A virus, hepatitis B virus, hepatitis C virus and HIV. These assays have undergone extensive performance evaluation using samples designated in the CTS in support of obtaining the Communautés Européennes (CE) mark for European market distribution. The ADVIA Centaur Immunoassay System represents an optimal platform for infectious disease testing because of its flexibility in allowing many different assay formats and protocols with multiple incubation steps and washes coupled with its combination of magnetic particle separation and chemiluminescent detection. Additional quality features of the system design are the sample integrity verification/check, the use of disposable sample pipette tips, clot detection, the ability for sensing liquid levels, the reagent aspiration verification/check, the automatic cascade reflex testing, repeat testing, and automated reagent inventory. The ADVIA Centaur has a maximum test throughput of 240 tests per hour. Minimal hands-on time is required as a result of the large onboard capacity for reagents and supplies combined with automated maintenance and monitoring features, which streamline operations and result in a walk-away through-put of up to 840 tests.
- 19 January 2003
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 41 (10) , 1289-98
The New European Directive on in vitro Diagnostics
The Directive on in vitro Diagnostic Medical Devices (IVDD 98/79/EC) was officially adopted by the European Union (EU) on December 7, 1998. The IVDD aims to supplement the legal framework of the European Community, which governs the conditions for the placing on the market of medical devices, by extending the already implemented legislation to the category of in vitro diagnostic medical devices (IVDs). They consist of those devices, including reagents and reagent products, calibrator materials or instruments, as well as specimen receptacles, intended by the manufacturer for the in vitro analysis of specimens derived from the human body. This directive has introduced at the European level common regulatory requirements across Europe for the safety, quality and performance of in vitro diagnostics (IVDs), incorporating them into medical device legislation. It harmonizes the conformity assessment procedures to be applied by manufacturers before they place IVDs on the market. For certain products expressly specified in the directive, of which the most important are used for the evaluation of the safety of blood supply and patient testing, the manufacturer will have to take into account in their performance evaluation the so-called "Common Technical Specifications" (CTS). These are needed to establish the performance characteristics of the IVDs in evaluation and have the same status as harmonized standards. In the meantime, the IVD directive has been transposed into national law in all EU countries. During a transitional period ending in December 2003, manufacturers will have the option of following pre-existing national regulatory processes or taking their IVDs through the new procedures as specified in the directive. Following this, starting from 7th December 2003, adherence to the directive regulations will become mandatory, and only IVDs bearing the "Communautés Européennes (CE) mark" can then be sold in the EU.
- 19 January 2003
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 41 (10) , 1289-98
The New European Directive on in vitro Diagnostics
The Directive on in vitro Diagnostic Medical Devices (IVDD 98/79/EC) was officially adopted by the European Union (EU) on December 7, 1998. The IVDD aims to supplement the legal framework of the European Community, which governs the conditions for the placing on the market of medical devices, by extending the already implemented legislation to the category of in vitro diagnostic medical devices (IVDs). They consist of those devices, including reagents and reagent products, calibrator materials or instruments, as well as specimen receptacles, intended by the manufacturer for the in vitro analysis of specimens derived from the human body. This directive has introduced at the European level common regulatory requirements across Europe for the safety, quality and performance of in vitro diagnostics (IVDs), incorporating them into medical device legislation. It harmonizes the conformity assessment procedures to be applied by manufacturers before they place IVDs on the market. For certain products expressly specified in the directive, of which the most important are used for the evaluation of the safety of blood supply and patient testing, the manufacturer will have to take into account in their performance evaluation the so-called "Common Technical Specifications" (CTS). These are needed to establish the performance characteristics of the IVDs in evaluation and have the same status as harmonized standards. In the meantime, the IVD directive has been transposed into national law in all EU countries. During a transitional period ending in December 2003, manufacturers will have the option of following pre-existing national regulatory processes or taking their IVDs through the new procedures as specified in the directive. Following this, starting from 7th December 2003, adherence to the directive regulations will become mandatory, and only IVDs bearing the "Communautés Européennes (CE) mark" can then be sold in the EU.